Royalty Pharma plc
RPRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $2,263,576 | $2,354,554 | $2,237,215 | $2,289,463 |
| % Growth | -3.9% | 5.2% | -2.3% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $2,263,576 | $2,354,554 | $2,237,215 | $2,289,463 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $2,000 | $52,000 | $177,106 | $200,084 |
| G&A Expenses | $236,671 | $249,748 | $227,303 | $182,826 |
| SG&A Expenses | $236,671 | $249,748 | $227,303 | $182,826 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $732,461 | $560,656 | $1,525,741 | $475,838 |
| Operating Expenses | $971,132 | $862,404 | $1,930,150 | $858,748 |
| Operating Income | $1,292,444 | $1,492,150 | $307,065 | $1,430,715 |
| % Margin | 57.1% | 63.4% | 13.7% | 62.5% |
| Other Income/Exp. Net | $38,369 | $207,938 | -$77,001 | -$189,514 |
| Pre-Tax Income | $1,330,813 | $1,700,088 | $230,064 | $1,241,201 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $858,983 | $1,134,834 | $42,832 | $619,728 |
| % Margin | 37.9% | 48.2% | 1.9% | 27.1% |
| EPS | 1.92 | 2.54 | 0.1 | 1.49 |
| % Growth | -24.4% | 2,440% | -93.3% | – |
| EPS Diluted | 1.91 | 2.53 | 0.1 | 1.49 |
| Weighted Avg Shares Out | 445,985 | 447,601 | 437,963 | 414,794 |
| Weighted Avg Shares Out Dil | 594,000 | 602,900 | 437,972 | 414,802 |
| Supplemental Information | – | – | – | – |
| Interest Income | $47,343 | $72,291 | $78,335 | $53,535 |
| Interest Expense | $225,512 | $187,187 | $187,961 | $166,142 |
| Depreciation & Amortization | $0 | $0 | $5,670 | $22,996 |
| EBITDA | $1,556,325 | $1,887,275 | $423,695 | $1,430,339 |
| % Margin | 68.8% | 80.2% | 18.9% | 62.5% |